The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Houston
Texas
77030
United States
Tel: 1-877-731-7527
Website: http://www.mdanderson.org/
319 articles about The University of Texas MD Anderson Cancer Center
-
Soliton Announces Submission for IRB Approval of Pivotal Cellulite Trial Protocol
7/16/2019
Soliton, Inc., a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center, announced that the company has submitted its pivotal cellulite clinical trial protocol for independent Institutional Review Board approval.
-
New biomarker-guided strategy has potential for liver cancer treatment
7/15/2019
Blocking IL-6 pathway may extend duration of immunotherapy and reduce side effects
-
Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations
7/8/2019
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
-
Soliton to Announce Cellulite Trial Data for 26-Week Period on July 15, 2019
7/8/2019
Soliton, Inc.,, a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center, announced that it will release the cumulative 26-week patient data from its cellulite proof of concept clinical trial on Monday, July 15, 2019.
-
Soliton Engages CRO to begin Pivotal Cellulite Trial
6/25/2019
Soliton, Inc., a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center, announced that the company has retained Emergent Clinical Consulting, LLC to serve as the Company's Contract Research Organization and manage its upcoming pivotal Cellulite Trial.
-
Cancer Research Innovator Dr. Donald Berry Joins OTraces' Scientific Advisory Board to Advance Early Cancer Detection
6/19/2019
OTraces' Diagnostics Capabilities Also Include Minimal Residual Disease Detection and Cancer Progression and Surveillance Blood Testing
-
Soliton to be Added to the Russell 2000 and 3000 Indexes on June 28, 2019
6/18/2019
Soliton, Inc. announced that the company will be added to the Russell 2000® and 3000® Indexes, effective after the market close on Friday, June 28, 2019, as part of the Russell Indexes annual reconstitution.
-
Drs. Lauren Averett Byers and Patrick Forde Join LUNGevity's Scientific Advisory Board
6/14/2019
LUNGevity expands its Scientific Advisory Board with two Career Development Awardees to deepen expertise in areas key to LUNGevity's research program
-
Lytix Biopharma AS Announces the Addition of Nobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma From the MD Anderson Cancer Center to its SAB and as Company Strategic Advisors
6/13/2019
Dr James Allison is Regental Professor and Chair of Immunology and Executive Director of Immunotherapy at the MD Anderson Cancer Clinic, University of Texas.
-
Soliton Confirms Conference Call to Discuss Recently Announced Significant Discovery and FDA Clearance for Today at 4:30 PM ET
6/11/2019
Soliton, Inc.,, a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center, will conduct a webcast to discuss its recent announcements regarding its significant discovery of acoustic subcision and its 510 clearance for its acoustic shockwave RAP device.
-
Study finds macrophages’ pathway to nurture PTEN-deficient glioblastoma
6/10/2019
MD Anderson discovery provides new druggable targets to test against lethal brain tumor
-
Soliton Announces Conference Call to Discuss Recently Announced Significant Discovery and FDA Clearance
6/5/2019
Soliton, Inc.,, a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center, will conduct a webcast to discuss its recent announcements regarding its significant discovery of acoustic subcision and its 510 clearance for its acoustic shockwave RAP device.
-
Lymphoma trial finds combination targeted therapy effective prior to chemotherapy
6/4/2019
MD Anderson Phase II study suggests patients with lymphoma subtype may be able to avoid chemotherapy in the future
-
Soliton Announces Significant Discovery of Acoustic Subcision for Treatment of Cellulite
6/4/2019
RAP technology combines selective disruption of fibrotic structures with production of new collagen in single non-invasive procedure
-
Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers
6/3/2019
Nivolumab plus ipilimumab meet primary endpoint of MD Anderson NEOSTAR Phase II trial
-
Study reports ibrutinib and venetoclax combo effective as front-line therapy for select chronic lymphocytic leukemia patients
5/29/2019
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia, have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas MD Anderson Cancer Center.
-
David Jaffray, Ph.D., Named Chief Technology and Digital Officer
5/21/2019
Joins MD Anderson from University Health Network/Princess Margaret Cancer Centre
-
Soliton Receives Approval for New Patent for its Acoustic Shockwave Technology
5/14/2019
Soliton, Inc. announced that the Japanese Patent Office has issued a notice of grant of patent Number 6503302, "Rapid Electrohydraulic Shockwave Generator."
-
Precision for Medicine To Provide Real-Time Laboratory Testing Services In Unique Lymphoma Patient Stratification Study
5/14/2019
The novel study will utilize Precision for Medicine's Houston-based CLIA certified lab to conduct real-time stratification studies on a specially selected group of B-Cell Lymphoma patients
-
Study shows MD Anderson-developed drug effective in overcoming ibrutinib resistance in mantle cell lymphoma
5/9/2019
A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered at the institution may help overcome resistance to treatment with ibrutinib in patients with mantle cell lymphoma.